Advances in Heart Failure: A Year of Discovery - Moving Forward with SGLT-2 Inhibitors
Published: 21 October 2020
-
Views:
61
-
Likes:
7
-
Views:
61
-
Likes:
7
-
15m 55s
-
23m 38sPart 3 SGLT-2 Inhibitors in Context
Overview
This programme focuses on assessing recent data on SGLT2 inhibitors that show they reduce CV outcomes, HF hospitalisations and mortality in HFrEF patients irrespective of T2DM .
The expert panel also discuss how new data from the EMPEROR-Reduced trial should be interpreted against complementary SGLT2 data and how these agents should be utilised in clinical practice.
Learning Objectives
- Evaluate Emerging Data on the Treatment of Heart Failure with SGLT-2 Inhibitors in Patients with or without T2DM
- Compare SGLT-2 Inhibitor Trial Data on the Treatment of Heart Failure in Patients with or Without T2DM.
- Recall the Impact of Emerging SGLT-2 Inhibitor Data in Heart Failure on Clinical Practice
More from this programme
Part 1
SGLT-2 inhibitors: Where Are We Now?
Part 2
SGLT2 Inhibitors in HFrEF: EMPEROR-Reduced
Part 3
SGLT-2 Inhibitors in Context
| 1 session | |
| SGLT-2 Inhibitors in Context | Watch now |
Faculty Biographies
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.
Prof Coats attended Melbourne Grammar School and studied at Oxford and Cambridge. He has a higher doctorates from Oxford (DM) and Imperial (DSc.).
Prof Coats was appointed Viscount Royston Professor of Cardiology at Imperial College in 1996 and Director of Cardiology and Associate Medical Director of the Royal Brompton and Harefield NHS trust. Professor Coats was appointed Dean of Medicine at the University of Sydney in 2002, and subsequently Deputy Vice-Chancellor. Professor Coats was most recently CEO of the Norwich Research Park, the UK's oldest and largest research and innovation park.
Prof Coats research interests are chronic heart failure, hypertension, and organizational…
Harriette Van Spall
Associate Professor
Dr Van Spall is a Principal Investigator for the Knowledge Translation and the Heart Failure programs at the Population Health Research Institute and an Associate Professor in the Division of Cardiology and Department of Medicine at McMaster University.
Dr Van Spall obtained her Doctor of Medicine degree from the University of Toronto, and a Master of Public Health degree from the Harvard School of Public Health. She completed postgraduate training in Internal Medicine, Cardiology, and Echocardiography at the University of Toronto. She has won several research awards, and her work has been published in high-impact medical journals, including JAMA, Lancet, Circulation, and Annals of Internal Medicine.
Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC
Dr Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Dr Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Dr Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.